6 research outputs found
Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.
<p>Values are median (25<sup>th</sup>–75<sup>th</sup> centile) unless noted.</p><p>* Based on weight discharge</p><p>Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.</p
Admission characteristics and response to ciprofloxacin therapy in 161 patients infected with nalidixic acid-susceptible and nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.
<p>Values are median (25<sup>th</sup>, 75<sup>th</sup> centiles) unless noted</p><p>* Based on disc-diffusion method</p><p><sup>‡</sup> Based on discharge weight</p><p>Admission characteristics and response to ciprofloxacin therapy in 161 patients infected with nalidixic acid-susceptible and nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.</p
Randomized controlled trials from which 161 adult patients infected with <i>V</i>. <i>cholerae</i> O1;treated with ciprofloxacin and completed 5day study were included in this analysis.
<p>There were 580 patients in total in these four studies, of whom 161 (28%) were infected with <i>V</i>.<i>cholerae</i> O1; treated with ciprofloxacin and completed 5 day study</p><p>Randomized controlled trials from which 161 adult patients infected with <i>V</i>. <i>cholerae</i> O1;treated with ciprofloxacin and completed 5day study were included in this analysis.</p
Nalidixic acid and ciprofloxacin MIC<sup>50</sup>and MIC<sup>90</sup> of 275 isolates of <i>V cholerae</i> O1 by year and source of strains obtained.
<p>Values are (μg/ml)</p><p>CT–Clinical trial; CLS–Clinical Laboratory Services, icddr,b</p><p>Nalidixic acid and ciprofloxacin MIC<sup>50</sup>and MIC<sup>90</sup> of 275 isolates of <i>V cholerae</i> O1 by year and source of strains obtained.</p
Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.
<p>Values are median (25<sup>th</sup>–75<sup>th</sup> centile) unless noted.</p><p>* Based on weight discharge</p><p>Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.</p
Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-susceptible strains of <i>V</i>. <i>cholerae</i> O1.
<p>Values are median (25<sup>th</sup>–75<sup>th</sup> centiles) unless noted</p><p>* Based on discharge weight</p><p>Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-susceptible strains of <i>V</i>. <i>cholerae</i> O1.</p